Insider Selling: CytomX Therapeutics (NASDAQ:CTMX) CFO Sells $124,053.66 in Stock

CytomX Therapeutics, Inc. (NASDAQ:CTMX) CFO Christopher Ogden sold 19,323 shares of the company’s stock in a transaction on Tuesday, March 17th. The shares were sold at an average price of $6.42, for a total transaction of $124,053.66. Following the completion of the sale, the chief financial officer directly owned 296,948 shares in the company, valued at approximately $1,906,406.16. The trade was a 6.11% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

CytomX Therapeutics Stock Performance

Shares of CTMX opened at $4.45 on Friday. The business’s 50-day moving average is $5.28 and its two-hundred day moving average is $4.13. The company has a market capitalization of $757.35 million, a P/E ratio of -111.25 and a beta of 2.44. CytomX Therapeutics, Inc. has a fifty-two week low of $0.40 and a fifty-two week high of $8.21.

CytomX Therapeutics (NASDAQ:CTMX) last issued its quarterly earnings data on Monday, March 16th. The biotechnology company reported ($0.22) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.08) by ($0.14). CytomX Therapeutics had a negative net margin of 22.79% and a negative return on equity of 19.77%. The company had revenue of $0.66 million during the quarter, compared to analyst estimates of $7.33 million. Analysts forecast that CytomX Therapeutics, Inc. will post -0.05 EPS for the current year.

Hedge Funds Weigh In On CytomX Therapeutics

A number of hedge funds have recently bought and sold shares of the business. Farther Finance Advisors LLC acquired a new stake in CytomX Therapeutics in the third quarter valued at approximately $25,000. Wells Fargo & Company MN increased its position in shares of CytomX Therapeutics by 83.2% in the fourth quarter. Wells Fargo & Company MN now owns 6,605 shares of the biotechnology company’s stock valued at $28,000 after buying an additional 3,000 shares in the last quarter. Invesco Ltd. acquired a new position in shares of CytomX Therapeutics during the 2nd quarter worth approximately $32,000. Pursue Wealth Partners LLC acquired a new position in shares of CytomX Therapeutics during the 2nd quarter worth approximately $33,000. Finally, Bay Colony Advisory Group Inc d b a Bay Colony Advisors purchased a new position in shares of CytomX Therapeutics during the 3rd quarter valued at approximately $34,000. Hedge funds and other institutional investors own 67.77% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have issued reports on CTMX shares. Wedbush boosted their price target on CytomX Therapeutics from $6.00 to $11.00 and gave the company an “outperform” rating in a report on Tuesday, March 17th. Guggenheim raised their price objective on shares of CytomX Therapeutics from $10.00 to $15.00 and gave the stock a “buy” rating in a research note on Wednesday. Weiss Ratings lowered shares of CytomX Therapeutics from a “hold (c-)” rating to a “sell (d)” rating in a report on Thursday. HC Wainwright boosted their target price on shares of CytomX Therapeutics from $10.00 to $17.00 and gave the company a “buy” rating in a research note on Monday, March 16th. Finally, Jefferies Financial Group increased their price target on shares of CytomX Therapeutics from $8.00 to $16.00 and gave the stock a “buy” rating in a report on Wednesday. Nine investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, CytomX Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $13.22.

More CytomX Therapeutics News

Here are the key news stories impacting CytomX Therapeutics this week:

• Positive Sentiment: Multiple high‑profile analyst upgrades and big price‑target increases (Jefferies, Barclays, Guggenheim, Wedbush and others) have pushed positive momentum and attracted buyers. Jefferies raises price target to $16
• Positive Sentiment: Trading volume spiked after the analyst upgrade cycle, suggesting the upgrades translated into real buying interest rather than just headlines. Strong trading volume after upgrades
• Neutral Sentiment: CytomX priced an equity offering to raise about $234 million, which materially extends runway and funding for the pipeline but will dilute existing shareholders. Timing and use of proceeds will determine the net effect. Equity offering announcement
• Neutral Sentiment: Short‑interest reports in recent filings show effectively zero reported short interest (data appears inconsistent/NaN), so short positioning is not clearly driving moves at this time. Short interest data (reporting)
• Negative Sentiment: CytomX missed Q1/quarterly estimates on both EPS and revenue, a concrete near‑term negative that increases uncertainty around execution and near‑term cash generation. Shares down on disappointing earnings
• Negative Sentiment: An analyst cut the Q1 EPS forecast, adding to concerns about near‑term financial performance and guidance. Q1 EPS forecast decreased
• Negative Sentiment: Clustered insider selling on March 17 (CEO Sean McCarthy, CFO Christopher Ogden, SVP Marcia Belvin and others) — sizable block sales by multiple senior executives — is dampening sentiment even if some sales are routine. Insider sales report
• Negative Sentiment: Some sell‑side and independent commentary warn that early clinical data may not yet justify elevated valuations, which could pressure momentum traders and cap further upside until clearer clinical/corporate catalysts arrive. Valuation caution commentary

CytomX Therapeutics Company Profile

CytomX Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of next-generation therapeutics based on its proprietary Probody® platform. The company engineers masked antibody prodrugs that remain inactive in healthy tissue but are selectively activated in the tumor microenvironment. This approach is designed to enhance the safety and tolerability of antibody-based therapies, particularly those targeting immuno-oncology pathways.

At the core of CytomX’s pipeline is Pacmilimab (CX-072), an anti–PD-L1 Probody therapeutic currently undergoing clinical evaluation for multiple solid tumor indications.